In Brief: Hi-Tech Pharmacal, OTC firm warned on water tests, John Taylor to leave FDA, NAD and ASA review claims
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal profits plummet; FDA warns OTC firm about GMPs; John Taylor to leave FDA; NAD refers claims for Vysera-CLS to FTC; Circulation Patch It claims lack support – ASA; and U.K. liquid OTC recalls.
You may also be interested in...
Class Action Continues Against Zantrex-3 Maker After Rejected Settlement
The ruling in US District Court for the Eastern New York District notes a Supreme Court decision in January in a separate case that also focused on settlement offers rejected by plaintiffs in civil litigation, a question on which US appellate courts have differed.
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.